Recent advances highlight innovative strategies, including hypoglossal nerve stimulation (HGNS), anti-obesity pharmacotherapy with glucagon-like peptide-1 receptor agonists, and upper airway muscle–targeted agents, which exemplify precision medicine approaches tailored to individual OSA phenotypes. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.